

The Role Of Glutamate In Mood Disorders & Schizophrenia

Tuesday, March 19, 2019 | 12pm ET | 9am PT

Glutamate is the predominant excitatory neurotransmitter in the nervous system, and glutamatergic dysregulation has been implicated in the pathophysiology of both mood disorders and schizophrenia.

In this webinar, James Murrough, MD, PhD, and Laura Rowland, PhD, will examine current research in this area, provide an overview of ionotropic and metabotropic glutamate receptors, discuss the rationale for development of glutamatergic modulators in the treatment of mood disorders and schizophrenia, and review various targets for therapy.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.



WEBINAR



Scan Me



James Murrough, MD, PhD

Associate Professor, Psychiatry and Neuroscience, and
Director, Depression and Anxiety Center for Discovery
and Treatment, Icahn School of Medicine, Mount Sinai



Laura Rowland, PhD


Associate Professor, Maryland Psychiatric
Research Center, Department of Psychiatry,
University of Maryland School of Medicine



Gerard Zitnik, PhD

Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. will be the moderator of this event.

Visit **www.PsychU.org** to learn more
and register today!

 Listen To PsychU Radio: PsychU.org/radio

 [linkedin.com/company/PsychU](https://www.linkedin.com/company/PsychU)

 [@PsychUCommunity](https://twitter.com/PsychUCommunity)